10月1日 - ** 药物开发商C4 Therapeutics CCCC.O 股价盘前上涨8%至2.40美元
** 该公司称已与辉瑞公司（Pfizer (link) PFE.N）合作测试一种癌症联合疗法
** CCCC将在已接受过至少一种治疗的多发性骨髓瘤（一种血癌）患者中测试其药物cemsidomide和辉瑞的elranatamab。
** 根据协议，辉瑞公司将免费提供艾拉他单抗（Elranatamab），该药以 Elrexfio 品牌销售，而 C4 Therapeutics 公司将领导并赞助这项早期试验，预计试验将于 2026 年第二季度开始。
** 截至上一交易日收盘，股价累计下跌 38
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.